OHDSI Estonia
Background
The University of Tartu in Estonia has an active health informatics research group led by Professor Jaak Vilo, Associate Professor Raivo Kolde, Dr. Sulev Reisberg, and around 15 other researchers, PhD students, and developers. They are involved in various OHDSI/OMOP-related initiatives, including IMI EMIF, IMI EHDEN, IMI OPTIMA, IMI PIONEER, EMA DARWIN, and Teaming for Excellence TeamPerMed projects. The group has conducted numerous health studies, developed new OHDSI/OMOP tools, and more.
In Estonia, two SMEs, STACC and Quretec, have received EHDEN certification for conducting OMOP ETL, and other institutions, such as Tartu University Hospital, have initiated converting their data to OMOP CDM. The Estonian Biobank, which is part of the University of Tartu, is also adopting OMOP.
Given the increased activity in Estonia related to OHDSI/OMOP, it was decided in December 2023 to establish the national OHDSI Estonia node to enhance coordination of activities and improve communication both within Estonia and with OHDSI collaborators beyond the country's borders.
Objectives
- Embrace OHDSI’s mission, vision, and values.
- Enhance communication within Estonia among national node members and externally with other OHDSI nodes and stakeholders, including the OHDSI European chapter.
- Coordinate and consolidate OHDSI/OMOP-related initiatives and tools within Estonia, such as mapping tables and coding lists.
- Advocate for and advance the utilization and proficiency of the OMOP common data model in Estonia.
Leading Organisation(s)
Lead Sulev Reisberg, Ph.D.
Co-lead Raivo Kolde Ph.D.
University of Tartu
Members
Name |
Organisation |
Sulev Reisberg |
University of Tartu |
Raivo Kolde |
University of Tartu |
Jaak Vilo |
University of Tartu |
Õie Renata Siimon |
University of Tartu |
Marek Oja |
University of Tartu |
Kerli Mooses |
University of Tartu |
Markus Haug |
University of Tartu |
Hendrik Šuvalov |
University of Tartu |
Harry-Anton Talvik |
University of Tartu |
Kunnar Kukk |
University of Tartu |
Sirli Tamm |
University of Tartu |
Maarja Pajusalu |
University of Tartu |
Andres Metspalu |
University of Tartu |
Lili Milani |
University of Tartu |
Priit Kleemann |
University of Tartu |
Sirje Lind |
University of Tartu |
Johannes Holm |
TEHIK |
Jarno Raid |
Tartu University Hospital |
Lenne-Triin Kõrgvee |
Tartu University Hospital |
Margus Jäger |
Quretec |
Kalev Koppel |
STACC |
Anders Eriksson |
Metrosert |
Liisa Loog |
Metrosert |
Data Partners
Data Source Name |
Organisation |
Data Type |
# Patients |
Link |
RITA MAITT |
University of Tartu |
10% random sample from national health databases 2012-2019 (150K patients) |
150K |
|
Estonian Biobank |
University of Tartu |
EHR of consent-based biobank, 200K participants |
200K |
|
CORIVA |
University of Tartu |
Data for about 85K Covid-19 cases and 340K random population controls followed up between 2018-2022 |
425K |
|
Tartu University Hospital, cancer center |
Tartu University Hospital, cancer center |
Most essential cancer-related data (MEDOC, the Minimal Essential Description Of Cancer) to OMOP (project "DIGItal Infrastructure for ONcology in Europe") |
NA |
Publications
-
Oja M, Tamm S, Mooses K, Pajusalu M, Talvik HA, Ott A, Laht M, Malk M, Lõo M, Holm J, Haug M. Transforming Estonian health data to the Observational Medical Outcomes Partnership (OMOP) common data model: Lessons learned. JAMIA open. 2023 Dec 1;6(4):ooad100.
-
Mooses K, Vesilind K, Oja M, Tamm S, Haug M, Kalda R, Suija K, Tisler A, Meister T, Malk M, Uusküla A. The use of prescription drugs and health care services during the 6-month post-COVID-19 period. Scientific Reports. 2023 Jul 19;13(1):11638.
-
Gandaglia G, Pellegrino F, Golozar A, De Meulder B, Abbott T, Achtman A, Omar MI, Alshammari T, Areia C, Asiimwe A, Beyer K. Clinical characterization of patients diagnosed with prostate cancer and undergoing conservative management: a PIONEER analysis based on big data. European Urology. 2023 Jul 5.
-
Voss EA, Shoaibi A, Lai LY, Blacketer C, Alshammari T, Makadia R, Haynes K, Sena AG, Rao G, van Sandijk S, Fraboulet C. Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study. EClinicalMedicine. 2023 Apr 1;58.
-
Uusküla A, Oja M, Tamm S, Tisler A, Laanpere M, Padrik L, Nygard M, Reisberg S, Vilo J, Kolde R. Prevaccination Prevalence of Type-Specific Human Papillomavirus Infection by Grade of Cervical Cytology in Estonia. JAMA Network Open. 2023 Feb 1;6(2):e2254075-.
-
Yang C, Williams RD, Swerdel JN, Almeida JR, Brouwer ES, Burn E, Carmona L, Chatzidionysiou K, Duarte-Salles T, Fakhouri W, Hottgenroth A. Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: a multinational real-world cohort analysis. InSeminars in arthritis and rheumatism 2022 Oct 1 (Vol. 56, p. 152050). WB Saunders.
-
Künnapuu K, Ioannou S, Ligi K, Kolde R, Laur S, Vilo J, Rijnbeek PR, Reisberg S. Trajectories: a framework for detecting temporal clinical event sequences from health data standardized to the Observational Medical Outcomes Partnership (OMOP) Common Data Model. JAMIA open. 2022 Apr 1;5(1):ooac021.